Sangamo Announces Expansion of Research Collaboration Agreement with Pfizer
News Jan 06, 2006
Sangamo BioSciences, Inc. has announced that it has entered into a second agreement with Pfizer Inc that expands the scope of existing research collaboration in the field of enhanced protein production.
Under the terms of the agreement, Pfizer will fund further research at Sangamo and Sangamo will use its zinc finger DNA-binding protein (ZFP) technology to develop additional cell lines for enhanced protein production.
"Over the past year we have enjoyed a very productive collaboration with Pfizer, the world's leading research-based pharmaceutical company," said Edward Lanphier, Sangamo's president and chief executive officer.
"We believe that the expansion of this agreement is evidence of our successful development and application of this technology to facilitate the generation of improved production cell lines with altered traits."
By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP transcription factors (ZFP TFs™) that can control gene expression and consequently, cell function.
Sangamo is also developing sequence-specific ZFP nucleases (ZFNs™) for targeted gene correction, gene disruption and gene insertion.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE